A Universal Aptamer for Influenza A Viruses: Selection, Recognition, and Infection Inhibition

Overview

Journal ACS Pharmacol Transl Sci

Publisher American Chemical Society

Specialty Biochemistry

Date 2024 Jan 17

PMID 38230279

Authors

Meng Wang

Meng-Chan Hao

Yueyue Huangfu

Ke-Zhu Yang

Xiao-Qing Zhang

Yuan Zhang

Jianjun Chen

Zhi-Ling Zhang

Affiliations

Soon will be listed here.

Abstract

It is crucial to develop universal inhibitors for viral inhibition due to the rapid mutation of viruses. Herein, a universal aptamer inhibitor was developed that enabled a single DNA molecule to recognize several hemeagglutinin (HA) protein subtypes, inducing broad neutralization against influenza A viruses (IAVs). Through a multi-channel enrichment (MCE) strategy, a high-affinity aptamer named UHA-2 was obtained, with its dissociation constants () for three different HA proteins being 1.5 ± 0.2 nM (H5N1), 3.7 ± 0.4 nM (H7N9), and 10.1 ± 1.1 nM (H9N2). The UHA-2 aptamer had a universal inhibition effect, by which it could broadly neutralize influenza A H5N1, H7N9, H9N2, H1N1, and H3N2 viruses. Universal aptamer inhibitors have the advantages of acquisition , stability, simple structure, small size, etc. This study not only develops a novel universal aptamer to achieve a broad inhibition effect on various IAVs, but also opens up an efficient strategy for the development of universal inhibitors against viruses.

Citing Articles

Advances in nucleic acid aptamer-based detection of respiratory virus and bacteria: a mini review.

Feng R, Liu Y, Liu Z, Wang L, Chen N, Zhao Y Virol J. 2024; 21(1):237.

PMID: 39350296 PMC: 11443872. DOI: 10.1186/s12985-024-02513-9.

References

Kim S, Choi J, Kim A, Lee S, Yoon M . Development of ssDNA Aptamers for Diagnosis and Inhibition of the Highly Pathogenic Avian Influenza Virus Subtype H5N1. Biomolecules. 2020; 10(8). PMC: 7465229. DOI: 10.3390/biom10081116. View

Guthmiller J, Han J, Utset H, Li L, Lan L, Henry C . Broadly neutralizing antibodies target a haemagglutinin anchor epitope. Nature. 2021; 602(7896):314-320. PMC: 8828479. DOI: 10.1038/s41586-021-04356-8. View

Zhang Y, Lai B, Juhas M . Recent Advances in Aptamer Discovery and Applications. Molecules. 2019; 24(5). PMC: 6429292. DOI: 10.3390/molecules24050941. View

Zhang Y, Juhas M, Kwok C . Aptamers targeting SARS-COV-2: a promising tool to fight against COVID-19. Trends Biotechnol. 2022; 41(4):528-544. PMC: 9340053. DOI: 10.1016/j.tibtech.2022.07.012. View

Haynes B, Wiehe K, Borrow P, Saunders K, Korber B, Wagh K . Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat Rev Immunol. 2022; 23(3):142-158. PMC: 9372928. DOI: 10.1038/s41577-022-00753-w. View

Krammer F, Smith G, Fouchier R, Peiris M, Kedzierska K, Doherty P . Influenza. Nat Rev Dis Primers. 2018; 4(1):3. PMC: 7097467. DOI: 10.1038/s41572-018-0002-y. View

Choi S, Lee C, Lee K, Choe S, Mo I, Seong R . DNA aptamers against the receptor binding region of hemagglutinin prevent avian influenza viral infection. Mol Cells. 2011; 32(6):527-33. PMC: 3887679. DOI: 10.1007/s10059-011-0156-x. View

Muyldermans S . Applications of Nanobodies. Annu Rev Anim Biosci. 2020; 9:401-421. DOI: 10.1146/annurev-animal-021419-083831. View

Dunning J, Baillie J, Cao B, Hayden F . Antiviral combinations for severe influenza. Lancet Infect Dis. 2014; 14(12):1259-70. PMC: 7164787. DOI: 10.1016/S1473-3099(14)70821-7. View

10.

Xu J, Shi P, Li H, Zhou J . Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential. ACS Infect Dis. 2020; 6(5):909-915. PMC: 7098069. DOI: 10.1021/acsinfecdis.0c00052. View

11.

Sun M, Liu S, Wei X, Wan S, Huang M, Song T . Aptamer Blocking Strategy Inhibits SARS-CoV-2 Virus Infection. Angew Chem Int Ed Engl. 2021; 60(18):10266-10272. PMC: 8014204. DOI: 10.1002/anie.202100225. View

12.

Hong S, Wan Y, Tang M, Pang D, Zhang Z . Multifunctional Screening Platform for the Highly Efficient Discovery of Aptamers with High Affinity and Specificity. Anal Chem. 2017; 89(12):6535-6542. DOI: 10.1021/acs.analchem.7b00684. View

13.

Kwon P, Ren S, Kwon S, Kizer M, Kuo L, Xie M . Designer DNA architecture offers precise and multivalent spatial pattern-recognition for viral sensing and inhibition. Nat Chem. 2019; 12(1):26-35. PMC: 6925649. DOI: 10.1038/s41557-019-0369-8. View

14.

Nimjee S, Rusconi C, Sullenger B . Aptamers: an emerging class of therapeutics. Annu Rev Med. 2005; 56:555-83. DOI: 10.1146/annurev.med.56.062904.144915. View

15.

Musafia B, Oren-Banaroya R, Noiman S . Designing anti-influenza aptamers: novel quantitative structure activity relationship approach gives insights into aptamer-virus interaction. PLoS One. 2014; 9(5):e97696. PMC: 4028238. DOI: 10.1371/journal.pone.0097696. View

16.

Li J, Zhang Y, Zhang X, Liu L . Influenza and Universal Vaccine Research in China. Viruses. 2023; 15(1). PMC: 9861666. DOI: 10.3390/v15010116. View

17.

Herschhorn A . Indirect Mechanisms of HIV-1 Evasion from Broadly Neutralizing Antibodies . ACS Infect Dis. 2022; 9(1):5-8. DOI: 10.1021/acsinfecdis.2c00573. View

18.

Subbarao K, Joseph T . Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol. 2007; 7(4):267-78. PMC: 7097526. DOI: 10.1038/nri2054. View

19.

Acter T, Uddin N, Das J, Akhter A, Choudhury T, Kim S . Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency. Sci Total Environ. 2020; 730:138996. PMC: 7190497. DOI: 10.1016/j.scitotenv.2020.138996. View

20.

Zhang Y, Xu C, Zhang H, Liu G, Xue C, Cao Y . Targeting Hemagglutinin: Approaches for Broad Protection against the Influenza A Virus. Viruses. 2019; 11(5). PMC: 6563292. DOI: 10.3390/v11050405. View